Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00862914
Recruitment Status : Completed
First Posted : March 17, 2009
Last Update Posted : October 16, 2012
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum

Brief Summary:
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.

Condition or disease
Naevi Malignant Melanoma

Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : July 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : March 2009

benign melanocytic naevi
dysplastic melanocytic naevi
cutaneous malignant melanoma

Biospecimen Retention:   Samples With DNA
Paraffin embedded melanocytic skin lesion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
dermatologic primary care clinic

Inclusion Criteria:

  • Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients with other forms of cancer in previous medical history
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00862914

Department of Dermatology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Principal Investigator: Prof. Dr. Peter Altmeyer Department of Dermatology and Allergology, Ruhr-University Bochum
Study Director: PD Dr. Falk G. Bechara Department of Dermatology and Allergology, Ruhr-University Bochum

Publications of Results:
Responsible Party: Michael Sand, Dr., Ruhr University of Bochum Identifier: NCT00862914     History of Changes
Other Study ID Numbers: 006
First Posted: March 17, 2009    Key Record Dates
Last Update Posted: October 16, 2012
Last Verified: October 2012

Keywords provided by Michael Sand, Ruhr University of Bochum:
Malignant Melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas